Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

2 terminated/withdrawn out of 10 trials

Success Rate

66.7%

-19.9% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

9(90.0%)

Phase 3

1(10.0%)

10Total

Phase 1(9)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07723248Phase 3Recruiting

A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

Role: lead

NCT05413421Phase 1Recruiting

Study of ORIC-944 in Patients With Metastatic Prostate Cancer

Role: lead

NCT06816992Phase 1Recruiting

ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC

Role: lead

NCT05315700Phase 1Recruiting

Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

Role: lead

NCT05227144Phase 1Completed

Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma

Role: lead

NCT06012721Phase 1Completed

Effect of Food on the Pharmacokinetics of ORIC-114

Role: lead

NCT04033328Phase 1Terminated

Study of ORIC-101 in Combination With Enzalutamide

Role: lead

NCT03928314Phase 1Terminated

Study of ORIC-101 in Combination With Anticancer Therapy

Role: lead

NCT03835637Phase 1Completed

Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects

Role: lead

NCT03324555Phase 1Completed

Study of ORIC-101 in Healthy Adult Subjects

Role: lead

All 10 trials loaded